51
|
Oaknin A, Moore K, Colombo N, Scambia G, Kim BG, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke G, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Lowe E, Bloomfield R, DiSilvestro P. Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
52
|
Friedlander M, Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Floquet A, Leary A, Sonke G, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Lowe E, Hettle R, Flood E, DiSilvestro P. Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
White R, Moore K, Roi D, Gordon A, Wood A. Rationalising short-term EVAR follow-up: can we reduce the follow-up burden for both patients and radiologists? Clin Radiol 2019. [DOI: 10.1016/j.crad.2019.09.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
54
|
Harb W, Patnaik A, Mahalingam D, Liu J, Wen P, Shapiro G, Bullock A, Juric D, Zheng L, Moore K, Patel M, Guttendorf R, Wang S, Kerstein K, Berk G, Cieslewicz M, Watnick J. A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
55
|
Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D, Farias-Eisner R, Banerjee S, Murphy C, Tanyi J, Hirte H, Konner J, Lim P, Hayes MP, Monk B, Kim S, Wang J, Pautier P, Vergote I, Birrer M. FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
56
|
Gourley C, Brown J, Lai Z, Lao-Sirieix P, Elks C, McGarvey H, French T, Milenkova T, Bloomfield R, Rowe P, Hodgson D, Barrett J, Moore K, DiSilvestro P, Harrington E. Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
57
|
Coward J, Kichenadasse G, Harnett P, Moore K, Barve M, Berg D, Garner J, Dizon D. Phase I study of intraperitoneal TRX-E-002-1 in subjects with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer: Three-month follow-up results of the dose escalation phase. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
58
|
Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M, Okamoto A, Moore K, Ben-Baruch N, Werner T, Oaknin A, Nam JH, Leath C, Nicum S, Cella D, Sullivan D, Ansell P, Dinh M, Aghajanian C, Bookman M. VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
59
|
Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
60
|
Nath S, Moore K. Photodynamic Therapy in a 3D Model of Ovarian Cancer. Bio Protoc 2019; 9:e3314. [PMID: 33654823 DOI: 10.21769/bioprotoc.3314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 07/21/2019] [Accepted: 07/21/2019] [Indexed: 11/02/2022] Open
Abstract
Photodynamic therapy (PDT), is a clinically-approved light-based anti-cancer treatment modality in which a photoactivatable photosensitizer is irradiated with an appropriate wavelength of light to generate cytotoxic molecules to kill cancer cells. In this article, we describe an in vitro PDT protocol using a 3-dimensional (3D) model of ovarian cancer that was established on beds of Matrigel. PDT was performed using a liposomal formulation of verteporfin photosensitizer (Visudyne®). The cancer cells were genetically-labeled with the fluorescent protein mCherry to facilitate the evaluation of the treatment response. This protocol is advantageous because the mCherry fluorescence is an indicator of cell viability, eliminating the need for external dyes, which often exhibit limited penetration and diffusion into 3D organoids. Additionally, Visudyne PDT achieves significant tumor-killing efficacy in a 3D model for ovarian cancer.
Collapse
|
61
|
Van Solingen C, Hennessy E, Scacalossi K, Ouimet M, Afonso M, Prins J, Koelwyn G, Ramkhelawon B, Maegdefessel L, Teupser D, Holdt L, Moore K. The Long Non-Coding Rna Chromr Regulates Cholesterol Homeostasis In Primates. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
62
|
Mayadev J, Enserro D, Brady W, Ghamande S, Moore K, Lin Y, DaSilva D, Aghajanian C, Schilder R. Positron emission tomography as an imaging biomarker after chemoradiation and immunotherapy for cervical cancer patients treated on GOG 9929. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
63
|
Gillen J, Enty M, Rowland M, Dvorak J, Ding K, Moore K. Evaluating the impact of a history of breast cancer on chemotherapy toxicities experienced in women with high grade serous ovarian cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
64
|
Essel K, Qiu Y, Thai T, Ding K, Burkett W, Zheng B, Moore K. Quantitative computed tomography image feature analysis predicts response to immune checkpoint inhibitors in gynecologic cancers. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
65
|
Essel K, Vetter M, Doo D, Greenwade M, Vesely S, Evans E, Strope B, Opara G, Powell M, Arend R, Salani R, Moore K. Prognostic factors associated with survival following platinum based therapy in advanced/recurrent endometrial cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
66
|
Burkett W, Holman L, Konecny G, Prendergast E, Ondunsi K, Moore K. Exploratory analysis of somatic BRCA mutations in endometrial cancer and its clinical implications. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
67
|
Gunness A, Pazderska A, Ahmed M, McGowan A, Phelan N, Boran G, Taylor AE, O'Reilly MW, Arlt W, Moore K, Behan LA, Sherlock M, Gibney J. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes. Hum Reprod 2019; 33:1727-1734. [PMID: 30020477 DOI: 10.1093/humrep/dey243] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 06/26/2018] [Indexed: 02/05/2023] Open
Abstract
STUDY QUESTION What information does androgen profiling using liquid chromatography tandem mass spectrometry (LC-MS/MS) provide in reproductive-age women with Type 1 diabetes (T1D)? SUMMARY ANSWER In T1D women, androstenedione proved most useful of the measured androgens in differentiating subgroups based on clinical phenotypes of hyperandrogenism (HA) and polycystic ovary syndrome (PCOS). WHAT IS KNOWN ALREADY The prevalence of HA and PCOS are increased in women with T1D. These observations are based on measurement of serum androgens using immunoassays, to-date no studies using LC-MS/MS have been reported in reproductive-age women with T1D. STUDY DESIGN, SIZE, DURATION This was a cross-sectional study with recruitment of three groups of reproductive-age women: women with T1D (n = 87), non-diabetic women with (N = 97) and without PCOS (N = 101). PARTICIPANTS/MATERIALS, SETTING, METHODS Using LC-MS/MS, we aimed to characterize androgen profiles and PCOS status in women with T1D, and interpret findings in relation to cohorts of non-diabetic women with and without PCOS. MAIN RESULTS AND THE ROLE OF CHANCE Compared to non-diabetic women, dehydroepiandrosterone/dehydroepiandrosterone sulphate (DHEA/DHEAS) ratio was lower (P < 0.05) in women with T1D. Testosterone levels were greater in T1D women with clinical HA and anovulation compared to those without clinical HA and with regular cycles, while androstenedione levels were greater in T1D women with HA and anovulation compared to those with HA and regular cycles and also those without HA and with regular cycles (P < 0.05 for all). Compared to T1D women without PCOS, the 18% of T1D women who had PCOS were younger with lower BMI, an older age of menarche, and were more likely to have a positive family history of PCOS (P < 0.05 for all). Androgen levels did not differ between women with T1D and PCOS compared to BMI-matched non-diabetic women with PCOS, but androstenedione levels were greater in T1D women with PCOS compared to obese women with PCOS (P < 0.05). LIMITATIONS, REASONS FOR CAUTION Relatively small subgroups of patients were studied, reducing the power to detect small differences. Free testosterone levels were not measured using equilibrium dialysis, and were not calculated - commonly used formulae have not been validated in T1D. WIDER IMPLICATIONS OF THE FINDINGS Androstenedione is a sensitive biochemical marker of clinical hyperandrogenism and PCOS in T1D. T1D women with PCOS are leaner than those without PCOS but are more likely to have a family history of PCOS. Women with T1D and PCOS have a similar biochemical phenotype to lean non-diabetic women with PCOS but differ from obese women with PCOS. The mechanisms underlying PCOS in T1D and its clinical significance require further investigation. STUDY FUNDING/COMPETING INTEREST(S) The study was part-funded by the Meath Foundation. The authors have no competing interests.
Collapse
|
68
|
|
69
|
Cook O, Moore A, Kaderka R, Moore K, Keall P, Martin J. PO-1111 Knowledge-Based Planning as a Real Time Review QA Feedback Tool in the TROG 1501 SPARK trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31531-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
70
|
Ozturk M, Moore K, Schafer S, Brace C, Hinshaw J, Lee F, Wagner M, Speidel M, Laeseke P. 04:03 PM Abstract No. 293 Cone-beam CT with augmented fluoroscopy: a novel approach for navigating airways and guiding transbronchial interventions. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
71
|
Rizvi I, Nath S, Obaid G, Ruhi MK, Moore K, Bano S, Kessel D, Hasan T. A Combination of Visudyne and a Lipid-anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer. Photochem Photobiol 2019; 95:419-429. [PMID: 30499113 DOI: 10.1111/php.13066] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Accepted: 11/27/2018] [Indexed: 01/08/2023]
Abstract
A major objective in developing new treatment approaches for lethal tumors is to reduce toxicity to normal tissues while maintaining therapeutic efficacy. Photodynamic therapy (PDT) provides a mechanistically distinct approach to treat tumors without the systemic toxicity of chemotherapy drugs. PDT involves the light-based activation of a small molecule, a photosensitizer (PS), to generate reactive molecular species (RMS) that are toxic to target tissue. Depending on the PS localization, various cellular and subcellular components can be targeted, causing selective photodamage. It has been shown that targeted lysosomal photodamage followed by, or simultaneous with, mitochondrial photodamage using two different PS results in a considerable enhancement in PDT efficacy. Here, two liposomal formulations of benzoporphyrin derivative (BPD): (1) Visudyne (clinically approved) and (2) an in-house formulation entrapping a lipid conjugate of BPD are used in combination with direct PS localization to mitochondria, endoplasmic reticulum and lysosomes, enabling simultaneous photodamage to all three organelles using a single wavelength of light. Building on findings by our group, and others, this study demonstrates, for the first time in a 3D model for ovarian cancer, that BPD-mediated photodestruction of lysosomes and mitochondria/ER significantly enhances PDT efficacy at lower light doses than treatment with either PS formulation alone.
Collapse
|
72
|
Rischin D, Gil-Martin M, González-Martin A, Brana I, Hou J, Cho D, Falchook G, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos K, Baranda J, Weise A, Fury M, Feng M, Li J, Lowy I, Mathias M. Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
73
|
Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu M, Moore K, Currie S, Bauman G, Warner A, Senan S. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.105] [Citation(s) in RCA: 80] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
74
|
Friedlander M, Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Floquet A, Leary A, Sonke G, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Lowe E, Bloomfield R, Disilvestro P. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy483.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
75
|
Senan S, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy433] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|